Illumina Inc (ILMN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $31.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Illumina Inc (ILMN) Financials: Revenue, Profit and Cash Flow
Illumina reported revenue of $4.34B for the fiscal year ended Dec 31, 2025, down 0.7% from the year before. That year, net income was $850.00M with a net margin of 19.6%, operating cash flow was $1.08B and free cash flow was $931.00M. The quarter ended Sep 30, 2026 had revenue of $1.13B and net income of $220.00M.
Revenue and Margins
The operating margin was 18.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.40B, a compound annual rate of 6.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.34B | -0.7% | 66.1% | 18.6% | 19.6% |
| Dec 2024 | $4.37B | -2.9% | 65.4% | -19.1% | -28.0% |
| Dec 2023 | $4.50B | -1.7% | 60.9% | -23.7% | -25.8% |
| Dec 2022 | $4.58B | +1.3% | 64.8% | -91.2% | -96.1% |
| Dec 2021 | $4.53B | +39.7% | 69.7% | -2.7% | 16.8% |
| Dec 2020 | $3.24B | -8.6% | 68.0% | 17.9% | 20.3% |
| Dec 2019 | $3.54B | +6.3% | 69.6% | 27.8% | 27.9% |
| Dec 2018 | $3.33B | +21.1% | 69.0% | 26.5% | 23.5% |
| Dec 2017 | $2.75B | +14.8% | 66.4% | 22.0% | 24.6% |
| Dec 2016 | $2.40B | N/A | 69.5% | 24.5% | 17.8% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 46.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.34B | $4.37B | $4.50B | $4.58B | $4.53B | $3.24B | $3.54B | $3.33B | $2.75B | $2.40B |
| Cost of revenue | $1.47B | $1.51B | $1.76B | $1.61B | $1.37B | $1.04B | $1.08B | $1.03B | $926.00M | $732.00M |
| Gross profit | $2.87B | $2.86B | $2.74B | $2.97B | $3.15B | $2.20B | $2.47B | $2.30B | $1.83B | $1.67B |
| Research and development | $967.00M | $1.17B | $1.35B | $1.32B | $1.19B | $682.00M | $647.00M | $623.00M | $546.00M | $504.00M |
| Operating income | $807.00M | -$833.00M | -$1.07B | -$4.18B | -$123.00M | $580.00M | $985.00M | $883.00M | $606.00M | $587.00M |
| Net income | $850.00M | -$1.22B | -$1.16B | -$4.40B | $762.00M | $656.00M | $990.00M | $782.00M | $678.00M | $428.00M |
| EBITDA | $1.42B | -$771.00M | -$666.00M | -$3.93B | $1.23B | $1.09B | $1.33B | $1.13B | $1.25B | $755.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.13B | $1.16B | $1.09B | $1.16B | $1.08B | $1.06B | $1.04B | $1.10B | $1.08B | $1.11B | $1.08B | $1.12B |
| Gross profit | $830.00M | $770.00M | $721.00M | $759.00M | $733.00M | $695.00M | $683.00M | $728.00M | $745.00M | $721.00M | $667.00M | $673.00M |
| Operating income | $305.00M | $245.00M | $209.00M | $202.00M | $227.00M | $214.00M | $164.00M | $174.00M | $741.00M | -$1.64B | -$111.00M | -$163.00M |
| Net income | $220.00M | $207.00M | $134.00M | $334.00M | $150.00M | $235.00M | $131.00M | $186.00M | $705.00M | -$1.99B | -$126.00M | -$176.00M |
Balance Sheet
As of Dec 2025, total debt of $1.99B exceeded cash and equivalents by $571.00M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.64B | $6.30B | $10.11B | $12.25B | $15.22B | $7.58B | $7.32B | $6.96B | $5.26B | $4.28B |
| Current assets | $3.29B | $2.75B | $2.61B | $3.56B | $2.71B | $4.48B | $4.45B | $4.49B | $2.98B | $2.32B |
| Cash and equivalents | $1.42B | $1.13B | $1.05B | $2.01B | $1.23B | $1.81B | $2.04B | $1.14B | $1.23B | $735.00M |
| Total liabilities | $3.92B | $3.93B | $4.37B | $5.65B | $4.48B | $2.89B | $2.70B | $3.05B | $2.29B | $1.97B |
| Short-term debt | $499.00M | $499.00M | $0 | $1.25B | $0 | $511.00M | $0 | $1.11B | $10.00M | $2.00M |
| Long-term debt | $1.49B | $1.49B | $1.49B | $1.49B | $1.70B | $673.00M | $1.14B | $890.00M | $1.18B | $1.06B |
| Shareholder equity | $2.72B | $2.37B | $5.75B | $6.60B | $10.74B | $4.69B | $4.61B | $3.76B | $2.75B | $2.20B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.81B | $6.65B | $6.56B | $6.64B | $6.18B | $6.09B | $6.18B | $6.30B | $6.01B | $6.08B | $10.04B | $10.11B |
| Total liabilities | $3.67B | $3.81B | $3.88B | $3.92B | $3.80B | $3.83B | $3.81B | $3.93B | $3.89B | $4.64B | $4.31B | $4.37B |
| Cash and equivalents | $1.29B | $1.04B | $1.09B | $1.42B | $1.05B | $934.00M | $1.11B | $1.13B | $869.00M | $920.00M | $1.11B | $1.05B |
| Shareholder equity | $3.15B | $2.84B | $2.68B | $2.72B | $2.38B | $2.26B | $2.37B | $2.37B | $2.13B | $1.44B | $5.73B | $5.75B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 86.2% of operating cash flow. Dividends and share repurchases together came to 79.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.08B | $837.00M | $478.00M | $392.00M | $545.00M | $1.08B | $1.05B | $1.14B | $875.00M | $779.00M |
| Capital expenditures | $148.00M | $128.00M | $195.00M | $286.00M | $208.00M | $189.00M | $209.00M | $296.00M | $310.00M | $260.00M |
| Free cash flow | $931.00M | $709.00M | $283.00M | $106.00M | $337.00M | $891.00M | $842.00M | $846.00M | $565.00M | $519.00M |
| Dividends paid | $1.00M | $1.00M | $1.00M | $0 | $511.00M | N/A | N/A | $735.00M | $3.00M | $29.00M |
| Share repurchases | $742.00M | $116.00M | $0 | $0 | N/A | $736.00M | $324.00M | $201.00M | $251.00M | $249.00M |
| Investing cash flow | -$55.00M | -$178.00M | -$231.00M | -$591.00M | -$1.07B | -$554.00M | $745.00M | -$1.81B | -$214.00M | -$515.00M |
| Financing cash flow | -$744.00M | -$570.00M | -$1.21B | $1.00B | -$51.00M | -$766.00M | -$897.00M | $594.00M | -$176.00M | -$296.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $419.00M | $201.00M | $289.00M | $321.00M | $284.00M | $234.00M | $240.00M | $364.00M | $316.00M | $80.00M | $77.00M | $224.00M |
| Capital expenditures | $40.00M | $40.00M | $38.00M | $55.00M | $31.00M | $30.00M | $32.00M | $29.00M | $32.00M | $31.00M | $36.00M | $51.00M |
| Free cash flow | $379.00M | $161.00M | $251.00M | $266.00M | $253.00M | $204.00M | $208.00M | $335.00M | $284.00M | $49.00M | $41.00M | $173.00M |
Frequently Asked Questions About ILMN
What is Illumina's annual revenue?
Illumina reported revenue of $4.34B for the fiscal year ended Dec 31, 2025.
How fast is Illumina's revenue growing?
Revenue was down 0.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -1.8%.
Is Illumina profitable?
Yes. Illumina reported net income of $850.00M for the fiscal year ended Dec 31, 2025, with a net margin of 19.6%.
How much free cash flow does ILMN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.08B minus capital expenditures of $148.00M produced free cash flow of $931.00M.
How much debt does Illumina have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.49B, short-term debt of $499.00M and cash and equivalents of $1.42B.
ILMN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts